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Abstract
Purpose—To establish a proof-of-concept for the efficacy of the anti-CD38 antibody 
daratumumab in the poor prognosis CD38+ CLL subtype.
Experimental design—The mechanism of action of daratumumab was assessed in CLL 
primary cells and cell lines using peripheral blood mononuclear cells to analyze antibody-
dependent cell cytotoxicity (ADCC), murine and human macrophages to study antibody-
dependent cell phagocytosis (ADCP) or human serum to analyze complement-dependent 
cytotoxicity (CDC). The effect of daratumumab on CLL cell migration and adhesion to 
extracellular matrix was characterized. Daratumumab activity was validated in two in vivo models.
Results—Daratumumab demonstrated efficient lysis of patient-derived CLL cells and cell lines 
by ADCC in vitro and ADCP both in vitro and in vivo, while exhibited negligible CDC in these 
cells. To demonstrate the therapeutic effect of daratumumab in CLL, we generated a disseminated 
CLL mouse model with the CD38+ MEC2 cell line and CLL patient derived xenografts (CLL-
PDX). Daratumumab significantly prolonged overall survival of MEC2 mice, completely 
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eliminated cells from the infiltrated organs and significantly reduced disease burden in the spleen 
of CLL-PDX. The effect of daratumumab on patient-derived CLL cell dissemination was 
demonstrated in vitro by its effect on CXCL12-induced migration and in vivo by interfering with 
CLL cell homing to spleen in NSG mice. Daratumumab also reduced adhesion of CLL cells to 
VCAM-1, accompanied by down-regulation of the matrix metalloproteinase MMP9.
Conclusions—These unique and substantial effects of daratumumab on CLL viability and 
dissemination support the investigation of its use in a clinical setting of CLL.
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CLL; Daratumumab; ADCC; ADCP; migration; adhesion; MMP9
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and is 
characterized by progressive accumulation of non-functional, apoptosis-resistant mature B-
cells in peripheral blood (PB), bone marrow (BM), and lymphoid tissues (1;2). The majority 
of the tumor cells in the blood are resting. However, heavy-water experiments have shown 
that CLL contains a small fraction of actively proliferating cells, with approximately 2% of 
cells newly generated each day (3). This proliferation occurs in specific structures known as 
proliferation centers localized in the lymph nodes (LN) and in the BM. Thus, CLL is 
considered a disease characterized by a dynamic balance between cells circulating in the 
blood and cells located in permissive niches in lymphoid organs (1;2).The former are 
primarily mature-looking small lymphocytes resistant to apoptosis whereas the latter are 
composed by lymphocytes that undergo either proliferation or apoptosis depending on the 
microenvironment.
CD38 was first reported to be associated with inferior outcome by Damle et al in 1999 (4), 
and confirmed later as a prognostic factor independent of IGHV mutation status (5). Patten 
et al demonstrated that CD38 expression in CLL is dynamic and changes as a result of 
contact with activated CD4+ T cells in proliferation centers, being CD38 specifically 
expressed on cells that are primed to proliferate in the LN (6). As a consequence, the 
expression of CD38 on CLL differs among lymphoid compartments, being higher in BM 
and LN compared to PB (7;8) and in the proliferating fraction of the tumor (9). The 
functional importance of CD38 in CLL extends beyond proliferation, as it appears to be 
linked to the tyrosine kinase ZAP-70 and characterizes CLL cells with high migratory 
potential (10). CD38 cooperates with CXCR4-induced migration (11) and sustains BCR-
mediated signaling (12). Finally, a role of CD38 in adhesion and tissue invasion was recently 
recognized. CD38 forms a macromolecular complex with the integrin CD49d and the matrix 
metalloproteinase MMP9, enhancing CD49d-mediated cell adhesion as well as MMP9 
expression and activity (13-15). This is of key relevance because CD49d surface expression 
strongly correlates with overall survival in CLL (16). All these properties make CD38 an 
attractive target for antibody therapy in CLL and other CD38+ hematologic malignancies 
such as multiple myeloma (MM) (17), non-Hodgkin’s Lymphoma (NHL), and B- and T-
acute lymphoblastic leukemia.
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The human anti-CD38 antibody daratumumab (DARA) has progressed to phase III clinical 
trials in patients with MM. DARA is a human IgG1 therapeutic monoclonal antibody (mAb) 
that binds to CD38. In 2015, the US FDA has approved DARA for MM patients, who have 
received at least three prior lines of therapy including a proteasome inhibitor and an 
immunomodulatory agent, or patients double refractory to these agents. Approval was based 
on two phase 2 studies of DARA monotherapy (16 mg/kg) in heavily treated patients 
(18;19). A pooled analysis of these studies revealed an overall response rate of 31%, 
including responses that deepened over time, and median overall survival of 19.9 months. 
DARA induces killing of tumor cells, mainly via complement-dependent cytotoxicity 
(CDC), antibody-dependent cellular cytotoxicity (ADCC) (20) and antibody-dependent 
cellular phagocytosis (ADCP) by macrophages (mϕ) (21) in MM and Burkitt lymphoma 
(BL) cell lines. In addition, DARA induces apoptosis upon secondary cross-linking (22). 
Recent studies have revealed previously unknown immunomodulatory effects of DARA 
where CD38-expressing immunosuppressive regulatory T and B cells, and myeloid-derived 
suppressor cells are highly sensitive to DARA treatment (23). It has also been shown that 
DARA can modulate the enzymatic activity of CD38 and potentially may lead to a reduction 
in immunosuppressive adenosine levels (24;25). This shift away from an 
immunosuppressive environment may lead to the generation of protective immune 
responses. Indeed, a concomitant increase of helper and cytotoxic T-cell absolute cell counts 
and production of IFNγ in response to viral peptides was observed. Additionally, an increase 
in T-cell clonality in subjects who responded to DARA versus subjects who did not respond 
was observed indicating an improved adaptive immune response (23).
Two additional anti-CD38 antibodies have also entered clinical trials for MM and other 
CD38+ hematologic malignancies, MOR202 (26) and isatuximab (SAR650984) (27), that 
are being tested alone and in combination with standard therapy.
The aim of this study was to evaluate the cytotoxic effect of DARA on CLL cells via CDC, 
ADCC and ADCP, as well as its effect on tumor cell-microenvironment interactions, using 
patient-derived CLL cells and CLL cell lines in in vitro and in vivo settings.
MATERIALS AND METHODS
Cell lines and patient samples
Primary tumor cells from 18 CLL patients (see clinical characteristics in Table 1), diagnosed 
according to the World Health Organization (WHO) classification criteria were used. 
Written informed consents of the patients were granted following the guidelines of the 
Hospital Clínic Ethic Committee (IRB) and the Declaration of Helsinki. Mononuclear cells 
were isolated from peripheral blood by gradient centrifugation on Ficoll (GE Healthcare) 
and used fresh or cryopreserved in liquid nitrogen in RPMI 1640 containing 10% DMSO 
(Sigma-Aldrich) and 60% heat-inactivated fetal bovine serum (FBS; Life Technologies) and 
maintained within the Hematopathology collection of the institution (IDIBAPS-Hospital 
Clínic Biobank, R121001-094). The Prolymphocytic Leukemia (PLL) cell lines, MEC1, 
MEC2 and JVM13 as well as the Burkitt’s lymphoma Daudi cell line were obtained from 
DSMZ. CLL primary samples and cell lines were cultured in RPMI 1640 or IMDM 
supplemented with 10% FBS, 2 mM L-glutamine, 50 μg/mL penicillin/streptomycin (Life 
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Technologies) and were maintained in a humidified atmosphere at 37°C containing 5% CO2. 
Normocin (100 μg/mL) (Invivo Gen) was added to the cell line cultures to prevent 
Mycoplasma contamination in cell lines that were routinely tested for Mycoplasma infection 
by PCR. The identity of all cell lines was verified by using AmpFISTR identifier kit (Life 
Technologies).
Therapeutic and CRPs blocking antibodies
A human IgG1 targeting CD38 (daratumumab, DARA) was generated by immunization in a 
HuMAb mouse (20).The human mAb IgG1-b12, specific for the HIV-1 gp120 envelope 
glycoprotein (28) was included in all experiments as an isotype control mAb. Both 
antibodies were provided by Genmab.
Anti-CD46 (clone TRA-2-10, Biolegend), anti-CD55 (clone 1C6, Hycult Biotech) and anti-
CD59 (clone YTH 53.1, AbD Serotech) antibodies were used to block complement 
regulatory proteins (CRPs).
Antibody-dependent cellular cytotoxicity (ADCC)
Target cells were labeled with 1 μM Calcein-AM (Life Technologies) for 30 minutes (min) 
at 37°C. Afterwards, cells were washed thrice with PBS, plated in triplicate at 1×104 cells/
well in 96-well round bottom plates, and pre-incubated (room temperature for 15 min) with 
10-fold serial dilutions of either isotype control (IgG1-b12) or DARA (range: 1 to 0.0001 
μg/mL) in RPMI 1640. DARA doses for in vitro studies were previously established (20). 
Culture medium was added instead of mAb to determine the spontaneous calcein release and 
1% Triton X-100 was used to determine the maximal calcein release. Thereafter, fresh 
human PBMC were added at an effector:target (E:T) ratio of 50:1, optimized in a previous 
report (20) and cells were incubated for 4 hours (hr) at 37°C. The plates were centrifuged, 
supernatant transferred into black plates (Thermo Scientific) and fluorescence was measured 
in a Synergy spectrophotometer (Bio-Tek) (excitation filter: 485 ± 20 nm; band-pass filter: 
530 ± 20 nm). The percentage of cellular cytotoxicity was calculated using the following 
formula:
Antibody-dependent cellular phagocytosis (ADCP)
Macrophages (mϕ) were generated from monocytes isolated from bone marrow of the hind 
legs of female SCID mice (C.B-17/Icr-Prkdcscid/Crl) (Janvier Labs) by flushing the femurs. 
The cells were cultured for 7 days in DMEM supplemented with 10% FBS, 2 mM L-
glutamine, 50 µg/mL penicillin/streptomycin, and 50 U/ml M-CSF (Cell Guidance), and the 
culture medium was renewed every 3 days. On day 7, mϕ were detached with 0.1% trypsin-
EDTA and characterized by flow cytometry (CD11b+, F4/80+) (mouse antibodies obtained 
from eBiosciences and Invitrogen, respectively). The mϕ were seeded at 2.5×105 cells per 
well into non-tissue cultured treated 24-well plates and allowed to adhere overnight. Target 
cells (primary CLL and cell lines) were labeled with 0.01µM Calcein-AM and added to the 
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mϕ at an E:T ratio of 1:1 in the presence of a fixed mAb concentration of 1 μg/mL. After 4hr 
of incubation, the non-phagocytosed target cells were collected. The mϕ were detached with 
0.1% trypsin-EDTA, added to the non-phagocytosed target cells and stained for F4/80 
expression.The amount of remaining target cells (calcein+ F4/80-) was determined on an 
Attune acoustic cytometer, and the percentage of killed target cells in the presence of DARA 
compared to isotype control was calculated using the following formula:
In vivo phagocytosis assay
In vivo phagocytosis assay was carried out as described by Overdijk et al (21). SCID beige 
mice (CB17.CG-PRKDC-LYST/CR, Charles River Laboratories) which lack NK cells, were 
inoculated with primary CLL cells or MEC2 cells (2×107 cells per mouse) into their 
peritoneal cavity, following a protocol approved by the Animal Testing Ethic committee of 
the University of Barcelona. Mice were randomly assigned into cohorts of three to five mice 
and received one intraperitoneal (i.p.) injection of 20 mg/kg of DARA or isotype control. 48 
hrs later, mice were sacrificed and peritoneal lavage (PL) done by injecting the cavity with 5 
mL of cold PBS. Total recovery of the peritoneal cells was evaluated by flow cytometry after 
staining with huCD45/CD19/CD5 antibodies (provided by Invitrogen and BD-Pharmigen, 
respectively). The relative percentage of remaining CLL cells from DARA-treated mice was 
derived from the isotype control group, which was set at 100%.
Complement-dependent cytotoxicity (CDC)
Target cells were labeled with 1μM Calcein-AM (Life Technologies) for 30 min at 37°C. 
Afterwards, cells were washed thrice with PBS, plated in triplicate at 1×105 cells/well in 96-
well round bottom plates, and preincubated (room temperature (29), 15 min) with 10-fold 
serial dilutions of either isotype control (IgG1-b12) or DARA (range: 10 to 0.01 μg/mL) in 
RPMI 1640. Culture medium was added instead of mAb to determine the spontaneous 
calcein release and 1% Triton X-100 was used to determine the maximal calcein release. 
Thereafter, 10% normal human AB serum was added and incubated for 45 min at 37°C. The 
plates were centrifuged, supernatants transferred into black plates (Thermo Scientific) and 
fluorescence measured in a Synergy spectrophotometer (Bio-Tek) (excitation filter: 485 ± 20 
nm; band-pass filter: 530 ± 20 nm). The percentage of cellular cytotoxicity was calculated 
using the following formula:
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In vivo homing
Homing experiment was done as previously described by Vaisitti et al (11). Briefly, NOD/
SCID gamma null (NSG) mice (bred in-house, animal facility, University of Barcelona) 
were randomly assigned into cohorts of four mice and pre-treated i.p. with 10 mg/kg of 
DARA, isotype control or anti-CXCR4 (R&D Systems). 24 hr later, mice were inoculated 
with fresh primary CLL (2×107 cells per mouse) via the tail vein following a protocol 
approved by the Animal Testing Ethic committee of the University of Barcelona. Mice were 
sacrificed 24 hr after tumor cell inoculation; PB, spleen and BM were recovered and the 
presence of tumor cells evaluated by flow cytometry after staining with huCD45/CD19/CD5 
antibodies.
Systemic MEC2 xenograft mouse model
SCID mice were preconditioned with 25 mg/kg of busulfan 24hr before inoculation via tail 
vein of MEC2 cells (107 cells per mouse), following a protocol approved by the Animal 
Testing Ethic committee of the University of Barcelona. One week later, mice were 
randomly assigned into cohorts of 6-7 mice. A saturating loading dose of 20 mg/kg DARA 
or isotype control i.p. was given on day 7 and thereafter 10 mg/kg weekly for 3 weeks. Mice 
were sacrificed if they lost 15-20% of weight and/or showed signs of disease. Survival 
studies were extended up to day 90 when the study was terminated. The presence of tumor 
cells was evaluated first macroscopically and then by flow cytometry. Cells from infiltrated 
organs were obtained by tissue homogenization. BM cells were obtained after flushing the 
femoral and tibia bones with RPMI 1640 media. These samples were filtered through 70 μm 
nylon sieves (BD Falcon). Erythrocytes were lysed using ACK buffer (Quality Biological 
Inc.).The cells were labeled with huCD45/CD19/CD5 antibodies and analyzed by flow 
cytometry. Organ samples were snap-frozen in OCT medium (Sakura Tissue Tek) or 
formalin fixed and embedded in paraffin. Tissue sections were stained with H&E and CD19 
(Dako) antibody and evaluated by Cell B Basic Imaging Software (Olympus).
CLL-Patient derived mouse xenograft (CLL-PDX)
On day 1, NSG mice were inoculated iv with fresh PBMCs from CLL (2×107 cells/mouse). 
On day 2, mice were randomly assigned to two groups (3-4 mice per group) and dosed i.p. 
with 20mg/kg of DARA or control isotype. Mice were sacrificed on day 5, PB, spleen and 
BM were recovered and the presence of tumor cells was evaluated by flow cytometry after 
staining with huCD45/CD19/CD5 antibodies.
Statistical analysis
Unpaired and paired T-tests or one-way ANOVA were used to assess statistical differences 
between groups by means of Graph Pad-Prism software 4.0. For Kaplan Meier survival 
curves SPSS19 software was used.
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RESULTS
Daratumumab induces ADCC
Ab-dependent killing via ADCC by FcγR-bearing effector cells accounts for the anti-tumor 
activity of DARA in models of MM and BL (20;30). The ability of DARA to induce ADCC 
on CLL cells was assessed by calcein-AM release assay using PBMCs from healthy donors 
as a source of effector cells (mainly NK cells and monocytes). CLL cell lines and primary 
cells were treated with increasing concentrations of DARA or isotype control. DARA 
induced significant cell lysis starting at doses as low as 0.01μg/mL in CD38+ CLL cell lines 
(Figure 1A), and at 0.001μg/mL in primary CLL cells (Figure 1B), reaching its maximum 
killing activity at 0.1-1μg/mL (mean±SD=31.9±11.6%). In contrast, the isotype control 
antibody did not induce significant cell lysis, tested at the maximum concentration of 
1μg/mL (mean±SD=12.4±11.6%) (Figure 1B). No ADCC induction was detected in CD38- 
CLL cases (Table 1: CLL7, CLL11 and MEC1 cell line). A summary of ADCC induction in 
CD38+ vs CD38- CLL primary cases is shown in Figure 1C. The degree of ADCC induction 
did not correlate with CD38 sABC for CLL cell lines and primary cells (r2=0.088) (Figure 
1D). Altogether, these data indicates that ADCC constitutes a mechanism of DARA activity 
in CD38+ CLL cells, but the extent of ADCC does not strictly correlate with CD38 
expression.
Daratumumab promotes CLL cell clearance by phagocytosis in vitro and in vivo
Recent results indicate that antibody-dependent cellular phagocytosis (ADCP) is a potent 
mechanism of action for DARA (21). We explored ADCP of CLL both in vitro and in vivo. 
To assess ADCP in vitro macrophages were generated from BM mouse monocytes 
stimulated with M-CSF. DARA induced ADCP in primary CLL cells (mean±SD= 23±4%) 
(Figure 2A). Representative flow cytometry profiles of CLL cells and macrophages after 
DARA treatment are depicted for CLL1 (Figure 2B). As observed for ADCC, phagocytosis 
was specimen-dependent and not strictly related to CD38 expression levels.
We next demonstrated the occurrence of ADCP in vivo. SCID beige mice, devoid of NK 
cells but with active macrophages were inoculated i.p. with primary CLL cells or the MEC2 
cell line as described in materials and methods. As shown in Figure 2C, the percentage of 
remaining viable CLL cells after DARA treatment was significantly reduced (mean±SD= 
46±5%; p<0.05, unpaired t-test) compared to the isotype control group at 100%. 
Remarkably, this decrease in cell number was detectable as early as 2hrs after DARA 
administration (data not shown). Figure 2D represents flow cytometry profiles showing the 
number of CLL cells (huCD45+/CD19+/CD5+) recovered from the intraperitoneal cavity 
after isotype control or DARA treatment. Taken together, these results demonstrate that 
ADCP may contribute to DARA anti-tumor activity against CLL cells both in in vitro and in 
vivo settings.
Daratumumab induces limited CDC of CLL cells
DARA was selected from a panel of human antibodies for its broad-spectrum killing activity 
against hematological cell lines. DARA was particularly differentiated for its potent CDC 
activity (20). We evaluated DARA-induced CDC activity in a panel of CLL primary cells 
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and cell lines (Tables 1 and S1). In the majority of primary CLL samples, CD38+ PLL cell 
lines (MEC2 and JVM13) and in CD38- cell line (MEC1), DARA did not induce significant 
cell death in the presence of normal human serum (10%). In five out of eighteen primary 
CLL cells, DARA induced just over 10% CDC (range: 10.4-25.6%). This limited CDC 
induction was not increased in the presence of higher human serum concentrations (data not 
shown). To explain the poor induction of CDC, we assessed the expression of complement 
regulatory proteins (CRPs) and the number of CD38 molecules/cell (CD38 sABC) on CLL 
cells. High expression of the CRPs: CD46, CD55, CD59 (mean± SD= 94±3 %; 92±4%; 
92±8%, respectively) was detected by flow cytometry in all CLL cell lines and primary 
cases, while only CD46 (88%) was highly expressed in the BL cell line Daudi (Tables 1 and 
S1) which was used as a positive control for CDC. Blocking antibodies against these CRPs, 
probed to increase CDC induction by DARA in Daudi, while no effect was observed in CLL 
cells. However, blockade of CRPs increased CDC induced by the anti-CD20 antibodies 
rituximab (RITUX) or ofatumumab (OFA) in some CLL cases (Figure S1).
CD38 expression in CD38+ CLL primary tumor samples (mean sABC±SD=1053±677) was 
lower than in CD38+CLL cell lines (mean sABC±SD=25,024±6,031), which was roughly 
ten-fold below that detected in Daudi (mean sABC±SD=292,131). A summary of Mean 
Fluorescence Ratio (MFIR) for CD38 and CRPs in CLL cells and cell lines is included in 
supplemental Table S2. Previous results in MM by Nijhof and cols have demonstrated that 
all-trans retinoic acid (ATRA) increases CD38 expression. We have analyzed this possibility 
in CLL. CLL cells (n=6) were pretreated with ATRA or left untreated for 48h. CD38 
expression was analyzed subsequently on these CLL cells and challenged to CDC assay. As 
shown in Figure S2A, CD38 MFI of CD19+CD5+ cells, was significantly (p<0.05) increased 
after ATRA treatment (average increase 30%), in a similar proportion than that shown for 
MM patient samples. A representative example is shown (Figure S2B). However, no CDC 
induction by DARA was observed in the cases analyzed (Figure S2C), indicating that this 
increase in CD38 expression was not sufficient to engage CDC.
In conclusion, these results indicate that DARA did not induce significant CDC in either 
CLL cell lines or primary CLL cells, and is probably due to high expression of CRPs and 
insufficient CD38 expression.
Daratumumab interferes with in vitro migration and in vivo homing
Homing of CLL cells to secondary lymphoid organs is mainly coordinated by the CXCL12/
CXCR4 axis (31). Using CLL primary cells and a xenograft mouse model, Vaisitti et al. 
demonstrated that CD38 synergizes with the CXCR4 signaling pathway and controls 
chemotaxis/homing of CLL cells through a close interaction between CD38 and CXCR4 in 
the membrane (11). Following this line of investigation, the effect of DARA on CLL cell 
migration was evaluated using a CXCL12 gradient. An anti-CXCR4 antibody was used as a 
positive control of migration blockade. In CD38+ CLL cells, DARA inhibited CXCL12-
mediated migration up to 70% (mean±SD= 44 ±16%; p<0.01; n=5), which was comparable 
to anti-CXCR4 treatment (Figure 3A). These results are in agreement with that previous 
report using the blocking anti-CD38 antibody SUN-4B7(11). We next examined DARA-
mediated signaling following CXCR4-CXCL12 interaction. The immediate early effect of 
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stimulation for migration is the activation of ERK1/2 (11). Phosphorylation of ERK1/2 in 
CLL tumor cells occurred shortly after CXCR4-CXCL12 ligation and peaked at five minutes 
after CXCL12 addition. Treatment with DARA reduced ERK activation by CXCR4-
CXCL12 in CLL1 and CLL12 while the ERK inhibition was less pronounced in CLL3 
(Figure 3B), illustrating heterogeneity in primary tumor cells.
We then validated these in vitro migration results using the in vivo homing mouse model 
described previously by Vaisitti et al (11). Using NSG mice, which lack NK cells and active 
macrophages, we analyzed the effect of DARA on primary CLL cell migration from PB to 
BM and spleen. In this model, NSG mice were pretreated (day 0) with DARA, isotype 
control or anti-CXCR4, followed by fresh CLL cell inoculation on day 1. PB, BM and 
spleen cells were isolated on day 2 and CLL cells were identified as CD45+/CD19+/CD5+. 
Representative flow cytometry profiles from a mouse spleen are shown in figure 3C. Cell 
enumeration showed that CLL cells rapidly move from PB and mainly migrated to the 
spleen and that DARA significantly reduced this migration (55% inhibition on average, 
p<0.05) (Figure 3D). Migration of CLL cells to BM was limited and was not affected by 
pretreatment of mice with DARA (data not shown). In conclusion, in vivo and in vitro 
results suggest that DARA hampers dissemination of CLL cells to secondary lymphoid 
organs.
Daratumumab inhibits CD49d mediated CLL cell adhesion by reducing MMP9 levels
In addition to migration, CD38 also plays a key role in cell adhesion through physical 
interaction with the integrin CD49d/CD29 (α4β1 integrin) (15) which is the strongest flow 
cytometry marker associated with poor prognosis in CLL together with IGVH mutational 
status (16) and MMP9 (13). In addition, the expression of CD38 correlates with that of 
CD49d. We analyzed the effect of DARA on CD49d/CD29-mediated adhesion of CLL cells 
to vascular-cell adhesion molecule-1 (VCAM-1), an essential component of extracellular 
matrix. As shown in Figures 4A and 4B, when compared to isotype control antibody, DARA 
significantly impeded the adhesion to VCAM-1 of CLL primary cells (n=4) and MEC2 cell 
line (mean± SD=38± 11%, p<0.01), with no significant differences with anti-CD49d 
blocking antibody used here as a positive control (mean± SD=49± 30 %).
Moreover, CD38-CD49d complex also recruits the matrix metalloproteinase MMP9 leading 
to the up-regulation and activation of this metalloproteinase (13-15). Thus, we investigated 
the effect of DARA on MMP9 expression, by analyzing the variations in MMP9 transcripts 
levels in CD38+CD49d+ CLL cells. As depicted in Figure 4C, CLL cell adhesion to VCAM 
increased MMP9 mRNA levels (mean±SD=2±1), and DARA completely abrogated both 
constitutive (p<0.01) and VCAM-induced (p<0.05) MMP9 expression. Altogether, these 
results demonstrate that DARA counteracts VCAM-1-mediated adhesion of CLL cells and 
induces the transcriptional down-regulation of MMP9.
Daratumumab prolongs overall survival in a systemic CLL mouse model and reduces 
tumor burden in CLL-PDX
We successfully established a systemic MEC2 model by intravenous cell inoculation in 
busulfan-preconditioned SCID mice, which retain NKs and macrophages that can function 
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as effectors for DARA activity. Previous attempts to establish a MEC2 mouse model failed 
using subcutaneous cell inoculation in nude mice (32).
One week after cell inoculation, mice were randomly assigned into two groups and were 
administered a total of four doses of DARA or isotype control following a weekly schedule 
(20/10/10/10 mg/kg). These doses were chosen based on dose escalation studies in MM 
(33). The isotype control-treated mice started to show signs of disease (mainly weight 
loss>20% and rough hair) starting at day thirty-two post cell inoculation (Figures 5A-B), 
and all mice in the control group were sacrificed by day 40. These mice showed systemic 
dissemination of disease in lung, kidney, ovaries, parathyroid glands and enlarged lymph 
nodes (identified as CD45+/CD19+. Figure 5C-D and Figure S3), resembling aggressive 
CLL. Of note, a similar disseminated CLL mouse model was described by Bertilaccio et al 
using the CD38-PLL cell line MEC1 in Rag2-/-γ-/- mice, and the authors demonstrated its 
value as a tool to assess the efficacy of chemotherapeutic agents(34). In several mice, BM 
and spleen infiltration was also observed (data not shown). In contrast, in the DARA-treated 
group, only one mouse harbored signs of illness and required euthanasia at day 41, while the 
remaining animals survived and did not develop life-threatening symptoms up to day 90, 
when the experiment was terminated (Figures 5A-B). By this day, the antibody 
concentrations in the serum of DARA-treated animals had dropped to 1.5 μg/mL (Figure 
S4). Interestingly, in this group of mice no MEC2 cells were found by flow cytometry or 
IHC in the commonly infiltrated organs like lung and kidney, contrasting with the 
remarkable predominance of malignant, human CD19+ cells observed in these secondary 
sites in control isotype-treated mice (Figure 5C-D), suggesting that these mice may be free 
of disease. These data suggest a strong anti-tumor activity and long-term survival of DARA-
treated mice in this model.
In order to develop a mouse model closer to CLL biology, we established a short time CLL-
PDX model using NSG mice, needed to avoid CLL clearance by mouse NKs. To provide 
this mouse model with FcγR-bearing effector cells, we selected CLL cases enriched in NKs 
and monocytes (Figure 5E). Fresh PBMCs from these patients were iv inoculated (day 1) 
and treated the following day (day 2) with DARA or control isotype. On day 5 mice were 
sacrificed and cells recovered from PB, BM and spleen. As described previously, cells 
mainly homed to the spleen, where a significant (*p<0.05) decrease of CLL cells was found 
in the spleen of DARA-treated group. No significant differences were found in BM or PB 
resident CLL cells between the two groups (Figure S5A). Off note, when the experiment 
was performed with a CLL sample with reduced numbers of effectors, the anti-tumoral 
effect of DARA was diminished (Figure S5B-C)
DISCUSSION
Targeted immunotherapy with mAbs has become the standard of care for successful 
treatment of many forms of cancer. In CLL, anti-CD20 antibodies (rituximab, ofatumumab 
and obinutuzumab), have demonstrated therapeutic benefit, alone and in combination with 
chemotherapy (35;36). Identification of new targets with a broader expression spectrum and 
potential for distinctive mechanisms could yield novel antibody therapeutics for a wider 
range of hematologic malignancies.
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In the last years, CD38 has gained momentum as a novel therapeutic target for patients with 
hematologic malignancies, namely MM (37;38), CLL and non-Hodgkin lymphoma. CD38 is 
an ectoenzyme belonging to the family of nucleotide-metabolizing enzymes, involved in the 
scavenging of extracellular nucleotides. CD38 catalyzes the synthesis of cyclic ADP-ribose 
and ADP-ribose from NAD, leading to an increase in cytoplasmic Ca2+concentration. CD38 
is used as a disease marker for leukemias and myeloma and it is considered a negative 
prognostic marker for CLL (4;5). Moreover, recent evidence indicates that CD38 forms a 
complex molecular network delivering growth and survival signals in CLL cells. CD38 
cooperates with chemokines and their receptors to influence cell migratory responses (11). 
These characteristics make CD38 an attractive target for CLL therapy. The use of an 
antibody such as DARA that specifically blocks CD38 might provide a new approach for 
interfering with deleterious growth circuits and for increasing the susceptibility of leukemic 
cells to conventional chemotherapy.
In this study, we have analyzed the potential therapeutic activity of DARA in CLL. DARA 
showed limited CDC activity in both primary CLL cells and CLL cell lines. Complement 
activation is strongly regulated by CRPs in vivo to prevent its uncontrolled amplification, 
including CD46, CD55, and CD59 that have been shown to mediate resistance to CDC 
induced by rituximab and less by ofatumumab (39). In fact, these proteins are overexpressed 
in a number of tumor types, and their upregulation has been postulated to contribute to mAb 
resistance in vivo (40).Our data show that CLL cell lines and primary cells display very high 
expression of the CRP, which may explain the limited sensitivity to DARA-mediated CDC 
in vitro.
Our results are the first to provide strong evidence that DARA induces lysis of CLL cells by 
FcγR mediated ADCC and ADCP through NK cells and macrophages, respectively. This 
cytotoxic effect is remarkable in CLL, where the mean ADCC induction was 35% at 
0.1μg/mL, being in the same range to those published for primary MM (19;32). In addition, 
ADCC does not correlate strictly with CD38 sABC in CLL cell lines or primary cells, 
indicating that at least in CLL the number of CD38 molecules on the cell surface may not be 
the only factor in driving Fc-mediated cytotoxicity of DARA. This observation suggests that 
other molecules within the immune synapse must control the extent of ADCC/ADCP by 
DARA. Activating receptors expressed on NK cells include FcγRIIIA, activating forms of 
Killer cell Ig-like receptors (KIRs) (KIR2DS and KIR3DS), NKG2D, and the Natural 
Cytotoxicity Receptors (NCR) called NKp30, NKp44, and NKp46 that are critical for 
optimal ADCC activity (41). NKG2D and NCRs are the most relevant receptors that 
stimulate responses to tumor target cells. In addition, inhibitory receptors counteract 
activating receptors as a means to tolerate mature NK cells. Thus, the overall make-up of 
these activating and inhibitory molecules on each individual CLL tumor cell may dictate the 
extent of ADCC by DARA (42). Along these lines, a recent study in MM have shown that 
blocking inhibitory KIRs with IPH2102, a human IgG4 monoclonal antibody that blocks the 
interaction of the three main inhibitory KIR receptors with their ligands, improves ADCC 
induced by daratumumab against MM cells (43).
Macrophages are tissue-resident immune cells that play a critical role not only in 
maintaining homeostasis and fighting infection but also in the progression of many 
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pathologies including cancer (44).Human macrophages express both activating and 
inhibitory FcγR and are involved as most prominent effector cell populations in mAb-
mediated tumor elimination in vivo. We have demonstrated that DARA induces 
phagocytosis of CLL by macrophages both in vitro and in vivo. In the in vitro model CLL 
cells and macrophages were co-cultured in the presence or absence of DARA. In the in vivo 
model, CLL cells were injected into the peritoneum of SCID beige mice, which are devoid 
of NK cells, but possess active macrophages in their peritoneal cavity.
Taken together these results provide evidence that anti-CD38 therapy with DARA may be 
relevant for CD38+ CLL cases.
We next explored if these in vitro mechanisms translate to in vivo tumor growth inhibition. 
To accomplish this task we developed two approaches. First, we successfully developed a 
MEC2 tumor model that showed engraftment efficacy of 100% and systemic disease 
involving mostly lungs, kidney, ovaries, parathyroid glands, enlarged lymph nodes and BM 
in a portion of the mice. This model is clinically relevant for CLL with leukemic infiltrates 
in isolated organs similar to that reported in CLL patients (45), presenting aggressive disease 
or transformation to Ritcher′s syndrome. In this model, treatment with relevant 
pharmacological doses of DARA efficiently prevented tumor progression and significantly 
prolonged survival. Mice treated with DARA showed long-term survival even though DARA 
dosing was stopped after 4 weeks and the antibody concentrations in the serum were 
minimal, suggesting that these mice were free of disease. Second, we developed a CLL-PDX 
model using NSG mice, to avoid CLL clearance by mouse NKs or phagocytes, and 
inoculating selected CLL enriched in NKs and monocytes to provide the system with FcγR-
bearing effector cells. In this model, DARA proved to reduce tumor burden in the mouse 
spleen, which constitutes the main infiltrated organ in this model (46). These results are the 
first to provide evidence that anti-CD38 therapy with DARA may be relevant for CD38+ 
CLL.
As described in the introduction, DARA activity may extend beyond its effect on the tumor 
cells, as it shows immunomodulatory effects on CD38-expressing immunosuppressive 
regulatory T and B cells and myeloid-derived suppressor cells (23). We have also 
demonstrated additional activities of DARA besides ADCC and ADCP in CLL. DARA has 
the potential to counteract microenvironment-derived signaling in protective cancer niches, 
such as LN and BM. We have demonstrated that DARA interferes with in vitro cell 
migration and in vivo homing of CLL cells to spleen in NSG mice. Transendothelial 
migration and organ invasion of malignant cells require proteolytic degradation of the 
vascular basement membrane and extracellular matrix of lymphoid tissues and MMPs play a 
key role in these processes. MMP9 is the predominant MMP expressed in CLL and is 
physiologically regulated by CD49d/CD29 and CXCL12, playing a key role in cell invasion 
and transendothelial migration (47). Moreover, MMP9 correlates with advanced stage 
disease and poor patient survival (48).We have demonstrated that DARA significantly 
reduces CD49d/CD29-mediated adhesion of CLL cells to VCAM-1 and, more importantly, 
downregulates both constitutive and adhesion-induced MMP9 expression. Based on the 
prominent role of MMP9 on CLL cell invasion, our results indicate that DARA treatment 
may impede CLL tissue infiltration that leads to progressive disease. Thus, in the era of B-
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cell receptor (BCR) kinase inhibitors, DARA immunotherapy opens a new horizon offering 
unique effects on tumor dissemination against CD38+ CLL cases. In conclusion, our results 
support DARA as a novel therapeutic approach for CD38+ CLL by not only inducing the 
classical FcγR-mediated cytotoxicity but also by harnessing microenvironment-derived 
survival signaling and blocking CLL dissemination to secondary lymphoid organs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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TRANSLATIONAL RELEVANCE
Chronic lymphocytic leukemia (CLL) remains an incurable disease where high CD38 
expression is associated with poor prognosis and identifies cells that are prone to 
proliferate. CD38 cooperates in migration, adhesion and invasion through its molecular 
association with CXCR4, MMP9 and CD49d. The human anti-CD38 monoclonal 
antibody daratumumab has shown efficient cell killing and a good safety profile in 
clinical trials in multiple myeloma. Here, we demonstrate that daratumumab also exerts 
significant cytotoxicity against patient-derived CLL cells, via ADCC and ADCP in vitro 
and in vivo. Furthermore, daratumumab interferes with CD38 signaling and reduces CLL 
cell adhesion, migration and homing. Moreover, daratumumab shows therapeutic activity 
in two mouse models. Thus, daratumumab improves overall survival in a systemic CD38+ 
MEC2 cell line mouse model and reduces tumor burden in CLL-patient derived 
xenografts. These results provide scientific rationale for the clinical development of 
daratumumab in poor prognosis CD38+CLL.
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Figure 1. Daratumumab induces ADCC in the presence of external effectors
Daudi cells, CLL cell lines, both CD38high (MEC2 and JVM13) and CD38low (MEC1) (A) 
and primary CLL cells (B) were treated with increasing daratumumab (DARA) doses 
(0.0001-1μg/mL) in the presence of PBMC from healthy donors at a E:T ratio of 50:1 for 4 
hours. Viability was then evaluated by calcein release assay. In panel B, ADCC induced by 
isotype control at the maximal dose of 1μg/mL is also depicted and the horizontal line 
represents the mean lysis. (C) ADCC induction by daratumumab (0,1 μg/mL) in CD38 high 
(≥30%) vs CD38 low (<30%) CLL primary cases. (D) The number of surface antibodies 
bound per cell (sABC) of CD38 was quantified in primary CLL cells and cell lines and 
plotted for correlation with ADCC induction by DARA (cell lines 0.1μg/mL and primary 
CLL 0.01μg/mL).
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Figure 2. Daratumumab induces ADCP in vitro and in vivo
(A) CLL cells were treated in triplicates with a fixed concentration (1μg/mL) of DARA or 
isotype control in the presence of mouse macrophages at a E:T ratio of 1:1, for 4 hours. 
Percentage of killed target cells was calculated by flow cytometry. CLL cells were identified 
as Calcein+ F4/80- and the percentage of killing by DARA was calculated according to the 
formula included in materials and methods. Daudi cell line was used as positive control. (B) 
Representative flow cytometry plots of in vitro ADCP. CLL cells and macrophages (mϕ) are 
clearly seen in the FSC/SSC density plot. The number of cells in the R8 gate was used to 
calculate the percentage of killed tumor cells. (C) In vivo phagocytosis was evaluated in 
SCID beige mice (n=3-5 per group) that were inoculated i.p. with primary CLL cells or 
MEC2 cell line (2×107 cells per mouse) and subsequently treated i.p with one dose of 20 
mg/kg of DARA or isotype control. The mice were sacrificed 48 hours later and cells from 
the peritoneum recovered and counted by flow cytometry as huCD45+CD19+CD5+ for 
primary CLL cells and CD45+CD19+CD5-for MEC2 cells. The percentage of residual 
leukemia cells after DARA treatment is plotted where the total number of cells remaining 
treated with the isotype control was set to 100% (p<0.05, unpaired t-test). (D) 
Representative flow cytometry plots where the R3 gate was used to calculate the percentage 
of killed tumor cells. The gating strategy started with cells in FSC/SSC (R1), then gating on 
CD45+, and finally CD19+CD5+.
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Figure 3. Daratumumab interferes with CLL cell migration and in vivo homing
(A) CLL cells were preincubated with the antibodies for 30 min at 4°C (30μg/mL for isotype 
control and DARA and 25μg/mL anti-CXCR4) and then assayed for migration in a CXCL12 
gradient. After 4h, CLL cells (CD19+ CD5+) in the lower chamber were counted in 
triplicates in a flow cytometer at fix flow rate. Total number of cells is graphed for 
representative CLL patients (n=5). Statistical differences between groups were assessed by 
paired t-test. (B) Western blot analysis of ERK activation after stimulation of CLL cells for 5 
minutes with CXCL12 (200ng/mL). Before stimulation, cells were serum starved for 2h and 
pretreated for 30 min with the corresponding antibodies (30μg/mL). (C-D) In vivo homing 
was assessed by iv inoculation of fresh CLL cells via tail vein in NSG mice, previously 
pretreated with the corresponding antibodies (10mg/kg, n=4 mice/group). After 20h, cells 
were recovered from spleen, labeled with huCD45/CD19/CD5 and counted in a flow 
cytometer. Representative density plots for each treatment are shown (C).The gating strategy 
started with cells in FSC/SSC (R1), then gating on huCD45+, and finally huCD19+ CD5+. 
(D) Total number of huCD45+CD19+CD5+ recovered from the spleen is plotted. Statistical 
differences between groups were assessed by unpaired t-test.
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Figure 4. Daratumumab hampers CLL adhesion to VCAM
Calcein-labeled primary CLL and MEC2 cells were pre-incubated with the corresponding 
antibodies (30μg/mL) and left to adhere for 30 min to plates pre-coated with VCAM-1 or 
BSA (non-specific adhesion). Anti-CD49d was used as positive control for inhibition of 
adhesion. Non-adhered cells were removed by extensive washing. (A) Representative phase-
contrast microscopy field images (×100) from adhesion to VCAM-1 of CLL9. (B) Adhered 
cells were then lysed and supernatants analyzed in a fluorimeter. Percentage of VCAM-1 
adhesion is expressed normalized to isotype control and after subtraction of BSA non-
specific adhesion (p<0.01, one way-ANOVA comparing the three groups together). (C) RT-
PCR for MMP9 was performed on the adhered cells to VCAM, using mGUS as endogenous 
control. (n=3, CLL4, CLL12 and CLL13) Expression levels for each sample are normalized 
to the corresponding isotype control and adhesion to BSA. ** = p<0.01 and * = p<0.05, 
unpaired t-test).
Matas-Céspedes et al. Page 21
Clin Cancer Res. Author manuscript; available in PMC 2017 September 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. In vivo efficacy of daratumumab
(A) Kaplan-Meier survival curves for MEC2 systemic mouse xenografts. Mice received 
DARA (n=7) or isotype control (n=6) weekly for four weeks, starting one week after cell 
inoculation. Then, mice were monitored twice a week for any sign of disease and sacrificed 
when body weight decreased 15-20%. All control mice had to be sacrificed between days 
23-38. One DARA-treated mouse became ill and was sacrificed on day 41. (B) Body weight 
changes in the isotype and DARA treated mice. (C) Cells from lungs and kidneys were 
isolated and labeled with huCD45/CD19/CD5. The presence of MEC2 cells was evaluated 
by CD19+CD5- (right panel) cells in the CD45+population (left panel). Representative flow 
cytometry density plots for one mouse of each cohort sacrificed at day 30 are shown. (D) 
IHC staining of H&E and CD19 of kidneys from isotype and DARA treated mice 
(magnification x400). (E) Density plots showing the percentage of CLL cells (CD19+ 
CD5+), T cells (CD3+ CD56-), NK cells (CD3- CD56+) and monocytes (CD14+). (F) Total 
number of huCD45+CD19+CD5+ recovered from the spleen of isotype ctrl and DARA 
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treated groups (CLL16: open symbols; CLL17: closed symbols). Statistical differences 
between groups were assessed by unpaired t-test.
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